LENZ Therapeutics Q2 EPS $(0.53) Beats $(0.62) Estimate, Sales $5.000M Beat $4.181M Estimate

LENZ Therapeutics (NASDAQ: LENZ) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.62) by 14.52 percent. This is a 32.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $5.000 million which beat the analyst consensus estimate of $4.181 million by 19.60 percent.